Cargando…

BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis

Non-alcoholic steatohepatitis (NASH) is a highly prevalent chronic liver disease. Here, we have investigated whether BAR502, a non-bile acid, steroidal dual ligand for FXR and GPBAR1, reverses steato-hepatitis in mice fed a high fat diet (HFD) and fructose. After 9 week, mice on HFD gained ≈30% of b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carino, Adriana, Cipriani, Sabrina, Marchianò, Silvia, Biagioli, Michele, Santorelli, Chiara, Donini, Annibale, Zampella, Angela, Monti, Maria Chiara, Fiorucci, Stefano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5311892/ https://www.ncbi.nlm.nih.gov/pubmed/28202906 http://dx.doi.org/10.1038/srep42801

Ejemplares similares

Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH
por: Marchianò, Silvia, et al.
Publicado: (2023)

Navigation in bile acid chemical space: discovery of novel FXR and GPBAR1 ligands
por: Finamore, Claudia, et al.
Publicado: (2016)

Gpbar1 agonism promotes a Pgc-1α-dependent browning of white adipose tissue and energy expenditure and reverses diet-induced steatohepatitis in mice
por: Carino, Adriana, et al.
Publicado: (2017)

Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation
por: Carino, Adriana, et al.
Publicado: (2019)

GPBAR1 Functions as Gatekeeper for Liver NKT Cells and provides Counterregulatory Signals in Mouse Models of Immune-Mediated Hepatitis
por: Biagioli, Michele, et al.
Publicado: (2019)

The bile acid receptor GPBAR1 (TGR5) is expressed in human gastric cancers and promotes epithelial-mesenchymal transition in gastric cancer cell lines
por: Carino, Adriana, et al.
Publicado: (2016)

GLP-1 Mediates Regulation of Colonic ACE2 Expression by the Bile Acid Receptor GPBAR1 in Inflammation
por: Biagioli, Michele, et al.
Publicado: (2022)

Impaired Itching Perception in Murine Models of Cholestasis Is Supported by Dysregulation of GPBAR1 Signaling
por: Cipriani, Sabrina, et al.
Publicado: (2015)

Discovery of a Novel Class of Dual GPBAR1 Agonists–RORγt Inverse Agonists for the Treatment of IL-17-Mediated Disorders
por: Fiorillo, Bianca, et al.
Publicado: (2023)

Correction to “Discovery of a Novel Class of Dual GPBAR1 Agonists–RORγt Inverse Agonists for the Treatment of IL-17-Mediated Disorders”
por: Fiorillo, Bianca, et al.
Publicado: (2023)

Insights on FXR selective modulation. Speculation on bile acid chemical space in the discovery of potent and selective agonists
por: Sepe, Valentina, et al.
Publicado: (2016)

Dissociation of Intestinal and Hepatic Activities of FXR and LXRα Supports Metabolic Effects of Terminal Ileum Interposition in Rodents
por: Mencarelli, Andrea, et al.
Publicado: (2013)

Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT/FOXOA1 Dependent Regulation of H(2)S Generation and Endothelin-1
por: Renga, Barbara, et al.
Publicado: (2015)

Analysis of Gastric Cancer Transcriptome Allows the Identification of Histotype Specific Molecular Signatures With Prognostic Potential
por: Carino, Adriana, et al.
Publicado: (2021)

Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinoma
por: Di Giorgio, Cristina, et al.
Publicado: (2023)

Discovery of a Potent and Orally Active Dual GPBAR1/CysLT(1)R Modulator for the Treatment of Metabolic Fatty Liver Disease
por: Fiorucci, Stefano, et al.
Publicado: (2022)

Expanding the Library of 1,2,4-Oxadiazole Derivatives: Discovery of New Farnesoid X Receptor (FXR) Antagonists/Pregnane X Receptor (PXR) Agonists
por: Finamore, Claudia, et al.
Publicado: (2023)

The Bile Acid Receptor GPBAR-1 (TGR5) Modulates Integrity of Intestinal Barrier and Immune Response to Experimental Colitis
por: Cipriani, Sabrina, et al.
Publicado: (2011)

Introduction of Nonacidic Side Chains on 6-Ethylcholane Scaffolds in the Identification of Potent Bile Acid Receptor Agonists with Improved Pharmacokinetic Properties
por: Finamore, Claudia, et al.
Publicado: (2019)

Correction: The Bile Acid Receptor GPBAR-1 (TGR5) Modulates Integrity of Intestinal Barrier and Immune Response to Experimental Colitis
por: Cipriani, Sabrina, et al.
Publicado: (2013)

The Bile Acid Sensor FXR Is Required for Immune-Regulatory Activities of TLR-9 in Intestinal Inflammation
por: Renga, Barbara, et al.
Publicado: (2013)

Divergent Effectiveness of Multispecies Probiotic Preparations on Intestinal Microbiota Structure Depends on Metabolic Properties
por: Biagioli, Michele, et al.
Publicado: (2019)

Discovery of ((1,2,4-oxadiazol-5-yl)pyrrolidin-3-yl)ureidyl derivatives as selective non-steroidal agonists of the G-protein coupled bile acid receptor-1
por: Di Leva, Francesco Saverio, et al.
Publicado: (2019)

Targeting Bile Acid Receptors: Discovery of a Potent and Selective Farnesoid X Receptor Agonist as a New Lead in the Pharmacological Approach to Liver Diseases
por: Festa, Carmen, et al.
Publicado: (2017)

Discovery That Theonellasterol a Marine Sponge Sterol Is a Highly Selective FXR Antagonist That Protects against Liver Injury in Cholestasis
por: Renga, Barbara, et al.
Publicado: (2012)

Hyodeoxycholic acid derivatives as liver X receptor α and G-protein-coupled bile acid receptor agonists
por: De Marino, Simona, et al.
Publicado: (2017)

Discovery of Bile Acid Derivatives as Potent ACE2 Activators by Virtual Screening and Essential Dynamics
por: Fiorillo, Bianca, et al.
Publicado: (2021)

Next-Generation Sequencing Analysis of Gastric Cancer Identifies the Leukemia Inhibitory Factor Receptor as a Driving Factor in Gastric Cancer Progression and as a Predictor of Poor Prognosis
por: Di Giorgio, Cristina, et al.
Publicado: (2022)

Discovery of a AHR pelargonidin agonist that counter-regulates Ace2 expression and attenuates ACE2-SARS-CoV-2 interaction
por: Biagioli, Michele, et al.
Publicado: (2021)

Metabolic Variability of a Multispecies Probiotic Preparation Impacts on the Anti-inflammatory Activity
por: Biagioli, Michele, et al.
Publicado: (2017)

Structure-based drug design targeting the cell membrane receptor GPBAR1: exploiting the bile acid scaffold towards selective agonism
por: Di Leva, Francesco Saverio, et al.
Publicado: (2015)

Bile Acids Activated Receptors in Inflammatory Bowel Disease
por: Biagioli, Michele, et al.
Publicado: (2021)

Alcoholic liver steatosis in mice is aggravated by low-protein diet and reversed by FXR agonist
por: Lívero, Francislaine Aparecida dos Reis, et al.
Publicado: (2012)

Hijacking SARS-CoV-2/ACE2 Receptor Interaction by Natural and Semi-synthetic Steroidal Agents Acting on Functional Pockets on the Receptor Binding Domain
por: Carino, Adriana, et al.
Publicado: (2020)

The HIV matrix protein p17 induces hepatic lipid accumulation via modulation of nuclear receptor transcriptoma
por: Renga, Barbara, et al.
Publicado: (2015)

Discovery of a Novel Multi-Strains Probiotic Formulation with Improved Efficacy toward Intestinal Inflammation
por: Biagioli, Michele, et al.
Publicado: (2020)

Decoding the role of the nuclear receptor SHP in regulating hepatic stellate cells and liver fibrogenesis
por: Cipriani, Sabrina, et al.
Publicado: (2017)

FXR an emerging therapeutic target for the treatment of atherosclerosis
por: Mencarelli, Andrea, et al.
Publicado: (2010)

(E)-7-Ethylidene-lithocholic Acid (7-ELCA) Is a Potent Dual Farnesoid X Receptor (FXR) Antagonist and GPBAR1 Agonist Inhibiting FXR-Induced Gene Expression in Hepatocytes and Stimulating Glucagon-like Peptide-1 Secretion From Enteroendocrine Cells
por: Stefela, Alzbeta, et al.
Publicado: (2021)

Bile Acids Activated Receptors Regulate Innate Immunity
por: Fiorucci, Stefano, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_alpneigm9t52d6d4279rpl4d5c